CardioHeal
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $340M
Overview
Developing engineered extracellular vesicle therapies to regenerate damaged heart tissue.
Cardiovascular
Technology Platform
A platform for engineering therapeutic extracellular vesicles (EVs) with specific regenerative cargo to promote repair in damaged cardiac tissue.
Funding History
1Total raised:$340M
IPO$340M
Opportunities
A successful regenerative therapy for heart failure would address a massive patient population with high unmet need.
Risk Factors
Preclinical stage carries high technical risk, and the field of cardiac regeneration has a history of clinical failures.
Competitive Landscape
Competes with other regenerative medicine approaches for heart failure, including stem cell therapies (e.g., Mesoblast) and gene therapies, though the EV space is less crowded.